Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers
Executive Summary
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.
You may also be interested in...
Takeda: 12 NMEs Poised To Launch In Five Years, And Deliver $10 Bn In Peak Sales
The Japanese pharma held its first investor day in New York, outlining the company's strategy to deliver long-term growth through a newly energized oncology, gastrointestinal and rare disease pipeline.
Takeda Sheds Products, Employees To Stada In $660m Move
Takeda offloads more assets as it focuses on core therapeutic areas and innovative drugs, this time a portfolio of products in emerging markets, with around 500 employees also affected.
Amgen Joins China Oncology Market Race With $2.7bn BeiGene Stake
As China embraces novel new drugs, oncology is quickly becoming the biggest opportunity for pharma to drive growth in this market. Amgen is the latest to jump on board through the purchase of a significant stake in BeiGene.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
